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Many reports indicate that pregnancy is a
diabetogenic state in which there is both insulin resistance
and an exaggerated maternal glucose and insulin response to
food ingestion. However, the magnitude of these aberrations
and their temporal relationship have not been adequately
characterized. This study utilizes the hyperglycemic clamp
technique to investigate the insulin secretory response and
tissue sensitivity to insulin under hyperglycemic conditions
in normal and gestational diabetic pregnancies. Our results
indicate that third trimester normal pregnancy is
characterized by an increased first phase (108 . 81+/-13 . 03
uU/ml) and second phase (228 . 57+/-43 .40 microunits/ml)
insulin secretory response as compared to non-pregnant
controls (72 . 93+/-15 . 76, 103 . 02+8/-12 . 43 ) (p<0.05).
However, C-peptide values did not mirror those of insulin in
that normal pregnant women during the third trimester of
pregnancy demonstrated a significantly lower C-peptide to
insulin ratio than either non-pregnant controls or
gestational diabetic women in their third trimester
(p<0.05). In contrast to normal pregnant women, gestational
diabetic women in their third trimester of pregnancy showed
no increase in insulin secretion.
Glucose uptake under hyperglycemic conditions
tended to decrease progressively through pregnancy and was
significantly lower than non-pregnant controls (10. 60+/-1. 19
mg/kg/min) in the third trimester of normal
pregnancy (7. 20+/-0. 79 mg/kg/min) and gestational diabetic
pregnancy(5.87+/-0.27 mg/kg/min) (p<0.05). Furthermore,
there was a significantly lower tissue sensitivity to
insulin (defined by the ratio of the glucose uptake to the
circulating insulin level during the final sixty minutes of
the study) in normal third trimester pregnancies ( 0. 03+/-0. 01
mg/kg/min per uU/ml) and gestational diabetic
pregnancies (0. 04+/-0. 01 mg/kg/min per uU/ml) as compared to
non-pregnant controls (0. 11+/-0. 02 mg/kg/min per uU/ml)
(p<0.05). Neither glucagon nor growth hormone were found to
be significantly different between the normal pregnant or
gestational diabetic groups.
These studies suggest that normal pregnancy is
indeed characterized by a tissue insensitivity to insulin
and that glucose tolerance (defined in this study as the
rate of glucose uptake) in normal pregnancy is primarily
related to the degree of compensatory hyperinsulinism.
However, this increased compensatory insulin secretion
appears to be absent in gestational diabetic women, thereby
contributing to the deterioration of glucose tolerance
observed in these women.
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INTRODUCTION
Gestational Diabetes: Clinical Aspects
Pregnancy, especially during late gestation, is
accompanied by many major alterations in maternal metabolism
of fuels, particularly glucose. During late pregnancy,
plasma glucose is significantly lower after an overnight
fast than in the nongravid condition'; furthermore, oral
glucose tolerance tests evoke a greater and more prolonged
hyperglycemic response as pregnancy proceeds which exceeds
postpartum values.2 Therefore, a degree of glucose
intolerance is a normal part of pregnancy; however, when
this intolerance becomes more exaggerated, one becomes a
gestational diabetic. How intolerant must one become to be
labelled abnormal? There were many attempts to define
normal limits on the oral glucose tolerance test for
diagnosing gestational diabetes. These patients would
require much closer prenatal care since the diagnosis of
gestational diabetes carries with it significant morbidity
and mortality for both mother and fetus. Furthermore, it is
believed that pregnancy puts an increased demand on
pancreatic beta-cell function which may unmask subclinical
pancreatic deficiency and thus results in defects in




In the United States, the criteria of 0' Sullivan and
Mahan (first proposed in 1964' and modified in 19734) has
been widely accepted for diagnosing pregnant women with
recognized abnormal glucose tolerance during pregnancy, in
other words, gestational diabetes. 0' Sullivan and Mahan
have also shown that by identifying those with gestational
diabetes and treating them, they were able to decrease
perinatal mortality in infants or gravid women over age 25.s
Their technique involved giving women a 100 gm oral glucose
load and then measuring whole blood glucose concentrations
(mg/dl) before, and then again one, two, and three hours
later after glucose ingestion. Normal limits were defined
as two standard deviations above the mean for each
value. (Table 1) Two or more values were required to be
elevated in order to meet the criteria for gestational
diabetes.6 In a 16 year follow-up, 0' Sullivan8 was able to
show that all but 2-3% of their original cohort returned to
normal glucose tolerance post-partum; however, 43.1%
developed diabetes mellitus later in life.
While the 3 hour GTT is a reliable method to identify
those pregnant women with gestational diabetes, it is not a
cost effective or convenient method to use as a general
screening test of all pregnant women.7 Moreover, ther would
be 38% of gestational diabetics missed if you just screened
5
pregnant women over age 25 with some other risk factor









Fasting 90 95 95 96
1 hour 163 180 180 172
2 hour 143 157 155 152
3 hour 127 139 140 131
Table 1: The original results of O'Sullivan and Mahan" s glucose tolerance test and their conversion of whole blood
glucose to plasma values. Adopted from Carpenter and Coustan.7 *Endorsed values by the National Diabetes Data
group and by the Second International Workshop-Conference on Gestational Diabetes MeUitus adopted from Carpenter
and Coustan's criteria.8.
O'Sullivan et al.4 devised a more useful method of
screening all pregnant women who, if test positive, can then
undergo the more formal 3 hour oral GTT. This screening
test involved measuring a fasting glucose level followed by
ingestion of a 50 gm glucose load then 1 hour measurements
of whole blood glucose using the Somogyi-Nelson analysis
which involves a chemical method of glucose detection
dependent on glucose's reducing properties.9 They used a
blood glucose value of greater than 13 0 mg/dl whole blood
(143 mg/dl, plasma) to be indicative of glucose intolerance.
(Plasma glucose values are generally 14% higher than whole
blood values using the same assay method.10) Carpenter and
6
Coustan' further refined this method by showing that by
lowering the threshold of plasma glucose to 135 mg/dl, you
would pick up the 13% of gestational diabetics from the pool
of women with GTT values of 13 5 to 14 3 (considered to be in
the normal range by O'Sullivan and Mahan's threshold).7 By
using the screening test with the lower threshold of 135
mg/dl plasma glucose (123 mg/dl whole blood) a sensitivity
close to 1.0 is achieved which means that the proportion of
pregnant women who would be missed by using this threshold
is close to zero.' Right now, the American Diabetes
Association recommends that all women be screened for
gestational diabetes between the 24th and 28th weeks of
pregnancy."
Statistics and Classification
The incidence of gestational diabetes in the United
States is estimated to be 2-3% of all pregnancies, with wide
variations reported.
a~"
Gestational diabetes is classified
as Class A diabetes by White's classification" and has been
further divided into more specific classes: hlt A2, B1#
depending upon whether or not the patient has an abnormal
OGTT without fasting hyperglycemia, with fasting
hyperglycemia, or marked fasting hyperglycemia with insulin
therapy (> 130 mg/dl), respectively." True gestational
7
diabetes means that the onset of diabetes occurs during
pregnancy (which usually is the third trimester) and the
patient reverts back to normal glucose homeostasis after
parturition.16 About 10% of Class A gestational diabetics
convert to Class B, because of the need for insulin therapy
to control blood sugar levels."
White's classification was devised to help predict
perinatal mortality and was based on pre-pregnancy
characteristics of the mother such as: duration of
diabetes, age of onset, and the presence or absence of
diabetic complications, such as vascular disease."
Subsequently, Pedersen et al." identified four
prognostically bad signs of diabetes during pregnancy:
diabetic ketoacidosis, pregnancy-induced hypertension,
pyelonephritis, and maternal neglect. Recently, it has been
shown that these prognostic indicators still hold up, even
with modern advances in care, including: ultrasound
monitoring, nonstress tests, biophysical profiles, oxytocin
challenge tests, the ability to assess fetal lung maturity,
and the ability to care for infants with prematurity and
respiratory distress syndrome."
Morbidity and Mortality
It is primarily fetal mortality, not maternal, that
occurs when pregnancy is complicated with diabetes. Even
8
maternal morbidity, when you exclude the risk of developing
diabetes later in life and rate of cesarean section, does
not seem to be different than in normal pregnant women if
good prenatal care is taken." Pregnant women with diabetes
do seem to be more likely to develop polyhydramnios and pre
eclampsia but most of this can be treated by close
monitoring with prenatal surveillance and ultrasound.20
Furthermore, the vascular and end organ deterioration that
all diabetics face, can occur at a more rapid pace after
delivery so careful monitoring of the EKG, renal function,
ophthalmic exams, and peripheral vascular disease is
important.21
Perinatal mortality rate in diabetic pregnant women is
higher than in nondiabetic pregnant women. Gabbe et al."
found that in a series of 260 women with classes B to R
diabetes mellitus, there was a total perinatal mortality of
46 per 1,000 as compared to 24 per 1,000 in the general
population; congenital malformations were responsible for
almost 50% of the deaths. Furthermore, in another report,
Gabbe and coworkers,22 found that there is also a high
frequency of congenital anomalies in women with Class A
(gestational) diabetes with 3 of 5 deaths associated with
congenital anomalies. Diamond et al.'s showed that the
perinatal mortality rate was increased in diabetic pregnant
patients with prognostically bad signs as compared to those
without (17.1% versus 7.3%). Becerra and colleagues25 found
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that in a population-based case-control study, infants born
to insulin-dependent diabetic mothers were eight times more
likely to have major malformations during the first year of
life. These malformations included various limb defects,
anomalies of the spine, and caudal dysgenesis. These
workers feel that diabetes does not seem to elicit a
specific group of defects but rather affects a wide variety
of organ systems, such as congenital heart disease, skeletal
disorders, neural tube defects and gastrointestinal
disorders.2"4 In addition, Becerra et al. found that
gestational diabetes incurs a significantly increased risk
for cardiovascular system malformations (Conus arteriosus,
transposition, Tetralogy of Fallot, patent ductus
arteriosus) , but only in gestational diabetics that used
insulin during pregnancy.23 In 1949, White found that
congenital anomalies accounted for only 8% of neonatal
deaths; thus, meticulous metabolic control of diabetic
pregnancies can eliminate almost all causes of mortality to
the infants with one exception, the persistent appearance of
congenital anomalies. This is consistent with the belief
that there is poor metabolic control during the early weeks
of gestation which coincides with the period of
organogenesis.1"5 Gestational diabetics that go on to
require insulin later in pregnancy, have a more severe
metabolic derangement than those that do not, thus it is
conceivable that they had an undetected derangement early in
10
pregnancy as well. In contrast to the belief that
macrosomia is characteristic of human diabetic pregnancies,
Pedersen and Molsted-Pedersen25 found that some fetuses of
diabetic pregnancies are actually smaller than normal in
early pregnancy by ultrasound. They were able to correlate
this "early growth delay" with an 18% risk of developing
congenital malformations, thus suggesting a common mechanism
occurring early in fetal life that disrupts fetal growth and
organogenesis.25 It is believed that the various metabolic
derangements that occur during the diabetic state, rather
than the disease diabetes mellitus itself, leads to
congenital defects during the period of organogenesis.24 The
specific teratogens have yet to be identified; however,
hyperglycemia has been shown to experimentally cause
congenital anomalies.26
Fetal complications in diabetic pregnancy include:
macrosomia with traumatic delivery, delayed organ maturity,
congenital anomalies, and intrauterine growth retardation.
Gabbe et al." found the morbidity of infants of Class A
diabetics in their population to equal approximately 25%,
with most morbidity comprised of hyperbilirubinemia. They
found that 65% of infants born to mothers of classes B to R
diabetes did experience some morbidity, including
hypoglycemia, hyperbilirubinemia, hypocalcemia, and
polycythemia." In addition, mean birth weight was
significantly elevated in these infants as compared to the
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general population." In a population of pregnant women
identified to have gestational diabetes during weeks 24-28
of gestation and treated in a high-risk clinic, Widness et
al.2' found that mean birth weight and rate of congenital
anomalies was increased in infants born to gestational
diabetic women, but the risk of other morbidities ( shoulder
dystocia, birth trauma, hypoglycemia, polycythemia,
hyperbilirubinemia, and respiratory distress ) that are
commonly reported, was not significantly different in their
study -
These recent reports of maternal and fetal morbidity and
mortality are much improved from reports from Priscilla
White in 194915 of an 18% fetal fatality rate. The credit
for this reduction is likely due to the modern concept of a
"diabetic team" that cares for gestational diabetics and all
pregnant women with diabetes.20 The team includes the
patient, the obstetrician, the clinical nurse specialist,
dietician, social worker, and neonatologist. Strategies
include achieving strict euglycemic control, first by diet
and if unsatisfactory, then by insulin therapy. In addition
adequate surveillance of the mother and the fetus is
achieved by frequent visits and exams, monitoring hemoglobin
AjC, ultrasound monitoring, and non-stress testing.
Thus, gestational diabetes has many similar clinical
characteristics to the other classes of diabetes in
pregnancy and appears to represent the lower end of a
12
spectrum of disease. It is obvious that it would be
fruitful to understand what "pushes these women over the
edge" during pregnancy to go from normal metabolic
homeostasis to problems with glucose intolerance and even
overt diabetes mellitus. Therefore, gestational diabetes
and pregnancy in general, can serve as a normal physiologic
model for development of a diabetogenic state and will help
us understand the pathophysiology of diabetes itself.
The Diabetogenicity of Pregnancy: Pathophysiology
Pregnancy can be considered to be a diabetogenic event
with most women surviving without ever developing clinically
apparent diabetes. The exact mechanisms behind this
tendency toward diabetes are not completely known, but the
consequence of these changes tends to reset the homeostasis
of carbohydrate metabolism during pregnancy. For example,
glucosuria is frequently found during normal pregnancy2* and
seems to be due to a decreased renal threshold for glucose."
Although there is conflicting evidence, it is generally
believed that there is a lowering of the fasting plasma
glucose and a decrease in carbohydrate tolerance during
normal pregnancy." As pregnancy progresses and the fetus
grows, insulin requirements of diabetics have shown to
increase, many previously unknown diabetics become unmasked,
and the ability of insulin to lower plasma glucose
13
concentration is diminished as insulin resistance develops.25
Furthermore, it is known that early pregnancy is devoted to
accumulation of maternal fuels whereas, late pregnancy is
characterized by the dramatic growth of the fetus and
placental unit. (Figure l)50 It is also interesting to note
that the greatest risk of developing gestational diabetes
occurs during the third trimester.12 Thus, there appears to
be a temporal relationship between the accelerated growth of
the fetus and the worsening diabetogenic effects of
pregnancy.
Figure 1 : Adopted from
Hyttenand Leitch, 1971.
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Hytten FE and Leitch L 1971, p.599.
Diabetes mellitus can be regarded as altering metabolic
homeostasis by causing maternal underutilization of
exogenous fuels in the fed state and overproduction from
endogenous reserves in the fasted state.50 Therefore, when
fasting plasma glucose is normal but there is abnormal
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glucose tolerance, the responsibility lies with
underutilization; however, in the presence of fasting
hyperglycemia one must consider defects in both
underutilization and overproduction of fuels.50 Lastly, with
severe diabetes and hypoinsulinemia, there is marked
disturbance in utilization.
"Accelerated Starvation" and "Facilitated Anabolism"
All of the metabolic changes described above occur in
normal pregnancy to an extent. Metzger and Freinkel2
proposed that "accelerated starvation" characterizes the
pregnant metabolic state after an overnight fast and
"facilitated anabolism" characterizes the fed state in
pregnancy- "Accelerated starvation" is thought to occur in
pregnancy with the mother's diversion to use of endogenous
fuels, occurring more guickly and to an amplified extent
during fasting, since the mother would have to maintain not
only her own oxidative needs but also the metabolic demands
of the developing fetus.' It was believed that if the
mother just simply recalled two-carbon fragments from the
breakdown of fatty acids or formed proteins, complex
carbohydrates, or glycerol, then the fetus would drain
essential building blocks and the mother would not have
sufficient fuels for herself.' Thus the concept of
"accelerated starvation" represents the state of the
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mother's reservoirs in late pregnancy, such that she cannot
conserve essential fuels as she would have under nongravid
starvation conditions.' There is a more rapid mobilization
of fat stores, increased FFA and triglyceride levels,
exaggerated increases in plasma and urinary ketone, greater
declines in plasma glucose, and greater muscle breakdown
during fasting in pregnancy.
5152J>
Felig et al.5' showed that
during a 84 hr fast during the second trimester of pregnancy
the response of plasma glucose, insulin, and ketone acids
was exaggerated and accelerated and seemed to be the result
of continuous glucose consumption by the fetus, not by any
defect in maternal gluconeogenesis. It has even been shown
that fasting from dinner, skipping breakfast, and not eating
again until lunch in normal pregnant women during the third
trimester will significantly precipitate all of the standard
characteristics of starvation.
"
On the other hand, you have "facilitated anabolism" which
occurs in the fed state during pregnancy. After eating,
there is a greater rise in plasma glucose and plasma
triglycerides than during late pregnancy.5* Since glucose
crosses the placenta freely and the placenta is relatively
impermeable to esterified fats," when the mother is fed the
more prolonged hyperglycemia seems to "facilitate" the
transfer of glucose across the placenta to the fetus.
Thomas et al.54 showed that diabetes and hyperglycemia
increases the placental transfer of glucose from the mother
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to the fetus in rats. The increases in plasma triglycerides
could provide fuel for the mother and thus also "spare"
glucose for the fetus. Furthermore, the hyperglycemia
results in a larger proportion of fuels being converted to
fats for later recall during the fasted state.29 There also
appears to be a greater fall of glucagon after eating during
pregnancy than in nongravids5' and this could also encourage
anabolism since you do not have the catabolic effects on the
liver caused by glucagon.29
Thus as stated by Metzger and Freinkel (1975) ,".. .the
exaggerated excursions of maternal glucose and insulin
appear to convert the metabolic topography from the gentle
foothills of the Berkshires to the majestic proportions of
the Alps.
"
(Figure 2) Freinkel, Phelps, and Metzger2' tested
this hypothesis by monitoring normal pregnant women and non
pregnant controls for 24 hours on a controlled diet and
found that normal late pregnancy is indeed accompanied by
greater premeal depressions and postmeal elevations in
plasma glucose and insulin than under nongravid conditions.
For those women who cannot compensate for the higher and
lower excursions of the plasma glucose with a concomitant
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The Insulin Secretory Response
Much is now known about the intricate cascade that leads
to insulin secretion. Stimulation of the beta-cell in the
pancreas by glucose leads to production of a compound named
"pre-proinsulin" in the rough endoplasmic reticulum. The
"pre" sequence, usually an amino acid sequence at the N-
terminal, quickly disappears as the newly synthesized
proinsulin molecule makes its way to the Golgi apparatus.
There, it is packaged into membrane bound granules with zinc
and a proteolytic enzyme. The enzyme cleaves the proinsulin
molecule at two locations leaving the insulin molecule and
the connecting peptide stored in stoichiometric quantities
in the storage granule.
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The initial stimulation of the beta-cell to release
insulin, leads to release of the granule's contents of
insulin, c-peptide, and a small amount of proinsulin. This
appears in studies as a sharp spike of hormone release
within 2-5 minutes of application of the stimulus and may
occur without protein synthesis.1* If the stimulus persists,
to 3 0-60 minutes, the proportion of proinsulin in the
secretion increases to 60-70% as protein synthesis and more
immature granules from the rough endoplasmic reticulum
directly secrete their contents.5'
Insulin is cleared by the liver, while proinsulin and C-
peptide are not. The metabolic clearance half-life of
insulin is about 5 minutes whereas for proinsulin it is
approximately 25 minutes57 and for C-peptide is 3 3 minutes.5*
Therefore, all three compounds are very much present in the
peripheral circulation and at the tissue level.
Furthermore, evidence shows that proinsulin can be
converted peripherally to insulin and proinsulin, itself,
may have some biological activity.57 Since C-peptide is
released in essentially equimolar amounts during
physiological glucose concentrations and is not cleared by
the liver, it has been used as a means for assessing





There are numerous hormonal changes occurring during
pregnancy and it is important to ask if it is in fact these
changes which cause the dramatic alterations described above
in carbohydrate, fat, and protein metabolism. Thus far, the
diabetogenicity of pregnancy can not be explained by common
characteristics of diabetes mellitus type 1. For example,
there is not slowed or decreased secretion of insulin, no
diminished insulin-to-glucagon ratio42, or non-
suppressability of glucagon." Thus, normal pregnancy and
gestational diabetes is often described as a state of
"insulin resistance" since there is glucose intolerance and
hyper insulinemia at the same time.
Glucagon is the primary physiologic stimulant of glucose
production, and acts by stimulating hepatic glycogenolysis
and gluconeogenesis. Fasting glucagon levels are elevated
in normal late pregnancy.42 The glucagon levels in
gestational diabetics have been reported to be high or
normal with no definitive answer.12 Glucagon does not seem
to be the cause of the diabetogenicity of pregnancy since
there is enhanced suppression of glucagon after an OGTT and
an increased insulin-to-glucagon ratio in pregnancy.42
A dramatic increase in plasma Cortisol levels occurs in
pregnancy, especially during the third trimester and
persisting several days post-partum.45 Transcortin levels
also rise, but this is secondary to increased estrogens.*4
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Cortisol acts as a counterregulatory hormone against insulin
that stimulates glucose production. There is no evidence of
increased secretion of Cortisol and it is believed by some
that there is a resetting of the negative feedback between
Cortisol and ACTH during pregnancy.44 Raised levels of
Cortisol can induce hyperglycemia and hyperinsulinemia,
similar to the way in which diabetes may be unmasked by
steroid use." However, there is no good evidence that
Cortisol levels are higher in pregnant diabetics versus
gestational diabetics versus pregnant non-diabetics."'45
Many investigators have shown that alterations in glucose
homeostasis during pregnancy first occurs as early as the
tenth week with further changes as pregnancy continues.*4
Thus some investigators point to the role of estrogens and
progesterones in glucose homeostasis since these hormones
begin rising in blood relatively early in gestation and are
prevalent throughout gestation. Studies with oral
contraceptives have shown that both estrogens and
progesterones can induce glucose intolerance and
hyperinsulinemia along with a decreased plasma glucose in
the fasted state.45 Estrogens and progesterones have been
shown to increase serum insulin levels through either direct
or indirect effects on the pancreatic islet beta-cells .**
On the other hand, natural estrogens have been shown to
improve carbohydrate intolerance in many species including
monkey, rabbit, rat, and man.45 Other studies have shown
21
that sex steroids suppress gluconeogenesis and enhance
glycogen synthesis in the liver in rats47 and estradiol has
been shown to alter many enzyme activities in the liver that
promote gluconeogenesis and glycogenolysis.44 Other
researchers believe that the deterioration of carbohydrate
metabolism associated with oral contraceptive use is due to
the progestin component which may act by reducing insulin
binding by decreasing insulin receptor concentrations.4*
However, Adams and Oakley49 believe that the main cause of
the alterations in carbohydrate metabolism of oral
contraceptives is due to a secondary increase in Cortisol
which in turn increases hepatic gluconeogenesis. Therefore,
there is a mixed picture of the mechanisms that sex steroids
influence and the effects that they produce on carbohydrate
metabolism during pregnancy. Thus far, no investigator has
found differences in concentrations of these hormones in
normal pregnants and gestational diabetics."*'*
Human placental lactogen (HPL) , a hormone of placental
origin, increases progressively during gestation from the
seventh week until delivery and has been thought by many
investigators to impair carbohydrate metabolism." However,
there is no correlation between HPL concentrations and those
of FFA or glucose either in normal pregnant women or
gestational diabetic women.52 No difference in circulating
HPL concentrations were found between nonpregnant women,
pregnant women, and gestational diabetic women in the
22
fasting state or in the hyperglycemic state.
"•"
Furthermore,
HPL concentrations correlate more strongly with the size of
the fetus than with anything else.50 During postpartum
administration of prednisolone, HPL, or sex steroids,
investigators were only able to reproduce the glucose
intolerance seen during the subject's pregnancies, when the
subject's ability to raise insulin secretion was restricted;
therefore, not really being able to induce a state of
insulin resistance as was believed to be occurring.50-55 HPL
secretion seems to be independent of acute changes in
metabolism and its exact influence on carbohydrate
homeostasis has not been fully elucidated.
Growth hormone acts as a counterregulatory hormone
opposing insulin and stimulating glucose production. Growth
hormone can cause diabetes in many normal animals and man.45
Growth hormone has been shown to cause carbohydrate
intolerance by increasing postprandial hepatic glucose
release and decreasing postprandial glucose uptake.54
However, concentrations of human growth hormone are low
during early pregnancy and do not increase as pregnancy
progresses.44 There also seems to be a blunted response of
growth hormone to hypoglycemia in pregnancy.55 Thus, there
does not seem to be a direct role for growth hormone in
carbohydrate metabolism in pregnancy. Prolactin is also
secreted by the anterior pituitary and unlike growth
hormone, its concentration in serum increases in pregnancy
23
and coincides with the increase in estrogens. Prolactin
levels again show sharp increases with breast feeding
episodes, however there is no evidence for a role of
prolactin in producing the diabetogenic effects of
pregnancy .
**•*
Catecholamines act in glucose homeostasis as
counterregulatory hormones. Neither epinephrine nor
norepinephrine seem to have an effect on the diabetogenicity
of pregnancy since the urinary output remains within normal
limits during pregnancy until labor begins.57
Kalkoff et al.44 found it useful to divide the hormonal
influences on carbohydrate and fat metabolism into two
periods: the first, includes the first half to two-thirds of
pregnancy and represents a state of "facilitated insulin
action" where estrogens and progesterones are elevated and
alter the maternal metabolism by emphasizing the uptake and
accumulation of nutrients in the liver, muscle, adipose
tissue, uterus, and breast; thus, acting insulin-like. The
last third of pregnancy represents a state of amplified fuel
metabolism, where the growth of the fetus dominates and HPL,
prolactin, and Cortisol achieve maximum levels at this time.
It was felt that the interaction of these hormones helps to
dictate which fuels will be available to the mother without
endangering nutrients to the fetus. These ideas also agree
with the fact that most gestational diabetics appear in the
third trimester. However, none of these hormones have been
24
shown to be different in normal pregnant women versus
gestational diabetic women and thus we cannot directly
implicate them as a cause for development of the
diabetogenicity of pregnancy.
Insulin Resistance
Earlier, we addressed the idea of insulin resistance and
said that the diabetogenic effects of pregnancy can be
explained by a state of insulin resistance. As pregnancy
progresses, it seems that the mother needs to increase her
levels of circulating insulin just to maintain
normoglycemia.21 Furthermore, women with IDDM who become
pregnant reguire progressively increasing amounts of insulin
in order to maintain euglycemia as pregnancy continues.5*
Thus, there is euglycemia or hyperglycemia with
hyperinsulinemia during pregnancy which fulfills most
definitions of insulin resistance.
"
Insulin resistance
could theoretically be due to an abnormal beta-cell
secretion of insulin, circulating insulin antagonists, or a
tissue resistance to insulin.5560
There have been two identified forms of insulin
resistance that occur at the tissue level: The first
involves receptor defects, mainly decreased numbers of
insulin receptors, and has been termed a decrease in insulin
sensitivity.5"' It is known that maximal stimulation of
glucose uptake occurs only when a small percentage
25
(approximately 10%) of insulin receptors are occupied."
This is a generalized phenomenon termed the "spare receptor"
theory59 and holds that cells have more receptors than is
necessary to elicit a maximal response and all these
receptors are potentially functional. This theory has been
corroborated experimentally.42*5 Therefore, the functional
response to insulin will increase as the receptors are
occupied until a critical occupancy is reached (10%) .
Thereafter, an increase in insulin receptor occupancy will
not further increase the functional response.59 There must
be a point distal to receptor binding in the cell which
becomes rate determining at this point. Accordingly, if
there was a defect in insulin sensitivity (a decreased # of
receptors) , the observed outcome of a decrease in insulin
receptors would be a decrease of insulin's effects at
submaximal concentrations of insulin and a correction to
normal insulin activity at maximally effective hormone
concentrations.59*2 Experimentally, this would produce a
rightward shift in the insulin-function dose-response
curve51*4 (Figure 3) .
The second form of insulin resistance has been termed a
decrease in "insulin responsiveness". This has been
attributed to a postreceptor defect in the cell since a
postreceptor defect would produce a decrease in insulin
activity at submaximal and maximally effective hormone
concentrations.59"*4 Thus a decrease in insulin
26
Figure 3: Adopted












Theoretical Insulin Dose-Response Curve
Figure 3
from Rizza et al, 1981
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responsiveness would produce a downward shift of the
insulin-function dose-response curve including a decreased
maximal insulin effect (Figure 3) . Postreceptor defects
could involve any step after initial binding of insulin to
its receptor and therefore, insulin responsiveness
represents a collection of multiple defects.59 If there was
both a decrease in insulin sensitivity and responsitivity,
experimentally one would see both a rightward shift of the
dose-response curve as well as a decrease in the maximal
insulin action64 (Figure 3) . Finally, by using the dose-
response curve, investigators have been able to better
characterize the specific causes leading to insulin
resistance in certain conditions.
27
There are many physiologic states in which insulin
resistance occurs besides pregnancy and gestational
diabetes. For example aging itself has been shown to be
accompanied by an increasing degree of insulin resistance."
The two most extensively researched areas of insulin
resistance are obesity and noninsulin dependent diabetes
mellitus. It has been shown in both animals and man that
there exists a decrease in insulin receptors in obesity
which leads to a decreased sensitivity to insulin as well as
marked intracellular abnormalities in glucose metabolism
which would lead to a decreased insulin responsiveness.6'
Kolterman et al.61 showed, using both euglycemic and
hyperglycemic clamp studies, that the insulin resistance in
obesity is not a homogeneous event. Some obese subjects
displayed classical decreased insulin sensitivity with
normal insulin responsiveness at maximally effective insulin
levels and the magnitude of the rightward shift of the dose-
response curve could be accounted for by the reduction in
insulin binding to receptors. However, other obese subjects
showed a combination of decreased insulin sensitivity and
decreased insulin responsiveness with a marked reduction in
the maximal response of the dose-response curve. Kolterman
et al." were able to further differentiate between these two
groups by showing that in the obese subjects with only a
defect in the number of insulin receptors, these subjects
displayed the least degree of hyperinsulinemia and insulin
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resistance. On the other hand, the group of obese subjects
with a combined receptor and postreceptor defects, were more
hyper insulinemic and more insulin resistant." The actual
event which causes resistance to develop in obesity has not
been fully elucidated but some evidence does point to
chronic hyperinsulinemia leading to a decrease in insulin
receptors in turn leading to insulin resistance.51"-5 Groop et
al.61 put forth the hypothesis that in obesity, the increased
amounts of FFA leads to increased oxidation of FFA, which in
turn causes impairment of glucose utilization by the
FFA/glucose cycle. It has also been shown that glucose
oxidation in large adipocytes is markedly decreased with
normal glucose transport into the cell, therefore, pointing
to a defect in intracellular glucose metabolism."2 Whatever
the defect, it seems that it is a reversible one, supported
by the evidence that weight loss can normalize impaired
glucose disposal.6" The intracellular defects in glucose
oxidative and nonoxidative pathways and their relationship
to insulin resistance will be discussed later on.
Noninsulin dependent diabetes mellitus (NIDDM) is yet
another state which is characterized by insulin resistance
and has been thoroughly studied. The majority of NIDDM
patients with significant fasting hyperglycemia are insulin
resistant, independent of obesity and age.5964"9 The current
evidence suggests that the resistance originates at the
tissue level. In another study using the euglycemic clamp
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technique, Kolterman et al." showed that in NIDDM as in
obesity the mechanisms of resistance are due to
heterogeneous causes. In the patients with only impaired
glucose tolerance, there was a rightward shift in the dose
response curves but maximal insulin action was normal.
Thus, these subjects showed a decreased sensitivity to
insulin with no decrease in insulin responsiveness
indicating only a defect in receptor numbers.
Alternatively, the patients with impaired glucose tolerance
and fasting hyperglycemia (indicating a more severe defect
in glucose homeostasis) displayed both a dose-response curve
shift to the right and a downward shift of maximal response
which was the more predominant change. Therefore, these
subjects display some defect in insulin sensitivity with the
dominant defect involving insulin responsiveness and a
postreceptor defect. Olefsky and Reaven69 have shown that as
the degree of insulin resistance worsens, there is more of a
defect in the insulin receptor binding in diabetes, but not
in patients with fasting hyperglycemia as well. Hence, as
diabetes and insulin resistance worsens, it seems that a
postreceptor defect becomes the more dominant defect over
decreased number of insulin receptors. Thus far, the
mechanisms behind initiating the insulin resistance in NIDDM
remains unknown. Groop et al.47 found that in NIDDM the
defect in glucose utilization cannot be explained by
increased FFA oxidation and is most likely a primary defect.
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Although the states of pregnancy and gestational diabetes
have not been examined as completely as obesity and NIDDM,
studies have shown that similar changes occur. The number
of insulin receptors on monocytes in gestational diabetics
is decreased during late pregnancy.™ Also, there has been
shown to be a decreased insulin response per unit of glucose
stimulus in gestational diabetes as compared to normal
pregnants.42 Along with these findings, Ryan et al.50
performed two-dose euglycemic clamp studies on normal
pregnant women and women with gestational diabetes and found
a shift to the right of the dose-response curve indicating a
decreased sensitivity (decreased number of receptors) in
both these groups as well. Furthermore, Ryan's studies also
indicated that their pregnant patients' resistance seems to
include a component of decreased responsivity as well,
indicated by a decrease in maximum insulin response.50 The
insulin resistance and decrease in maximum responsivity
appeared to be worse in gestational diabetics than in normal
pregnant women.50 Thus, one can imply from this study that
the insulin resistance of pregnancy and gestational
diabetes, like that found in obesity and NIDDM, involves
both a receptor and post-receptor defect. As in obesity,
these defects were found to be reversible with the women
reverting back to normal glucose and insulin responses post
partum.50 However, this study only "suggests" a defect in
maximal responsivity and more complete studies are needed of
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normal pregnant women and gestational diabetics to prove
their findings.
Significance and Effects of Hyperglycemia on Mother and
Fetus
Since fasting hyperglycemia occurs as insulin resistance
worsens and hyperglycemia has been shown experimentally to
be a teratogen26, it's important to ask if hyperglycemia acts
as a compensatory mechanism by the body to increase glucose
uptake into cells. Furthermore, does the fate of glucose
differ whether its uptake is stimulated by hyperinsulinemia
or hyperglycemia? The uptake of glucose into peripheral
tissues can be stimulated by both insulin, as well as
glucose per se.7"2 As insulin resistance develops and
worsens in NIDDM, glucose is not taken up by peripheral
tissues as efficiently and hyperglycemia develops. Thus the
hyperglycemia that develops will itself promote glucose
uptake and help to compensate for defects that are present."
Once glucose enters the cell it can undergo either
oxidation to produce ATP through glycolysis, the Krebs
cycle, and oxidative phosphorylation, or it can undergo non-
oxidative metabolism to form glycogen, lactate, or fatty
acids. Thorburn et al.'4 have shown that in normal subjects,
insulin can regulate glucose oxidation by suppressing FFA
and fat oxidation; however, when maximal suppression is
attained, the rate of glucose uptake into the cell, rather
32
than the insulin level, regulates the fate of intracellular
glucose. Insulin appears to regulate the fate of glucose by
controlling the availability of FFA substrate, thus there is
some degree of competitive inhibition between fat and
glucose oxidation.'4 Both insulin and glucose can stimulate
glucose oxidation, but under normal conditions insulin is
the more important stimulator due to its antilipolytic
effects.'5"5 As glucose oxidation is decreased, there is a
reciprocal increase in nonoxidative glucose metabolism,
mostly glycogen synthesis.'4 In NIDDM, Henry et al.'5 have
shown that hyperglycemia does compensate for insulin-
impaired glucose uptake and the distribution of
intracellular glucose into oxidative or nonoxidative
pathways depends only on the rate of glucose uptake into the
cell. FFA and fat oxidation remain sensitive to insulin in
these patients and thus are suppressed due to the prevailing
hyperinsulinemia in NIDDM.75 Furthermore, postabsorbtive
hyperglycemia in NIDDM can compensate egually for both
oxidative and nonoxidative pathways of glucose metabolism."
Therefore, the development of hyperglycemia in insulin
resistant states tends to act as a compensatory mechanism to
normalize glucose uptake as well as intracellular glucose
metabolism.
Considering that clinically, the fetus is at the most
risk for mortality or morbidity due to gestational diabetes,
how does the maternal insulin resistance, diabetes,
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hyperglycemia, and greater oscillations in metabolites
influence the fetus. Since it is almost impossible to do
invasive studies on human fetuses, many of these studies
have used animals, such as sheep and rats. The streptozocin
treated rat has been used as a model for gestational
diabetes because streptozocin induces diabetes in these
rats. However, the fetuses of these rats tend to weigh less
than normal fetuses and this effect coincides with a
reduction in fetal insulin levels; this contrasts with human
fetuses of diabetic women which tend to be macrosomic with
hyperinsulinemia.'" Therefore, this model cannot be directly
related to human diabetes. However, using this model,
Thomas and colleagues showed that diabetes itself causes
increased placental transfer of glucose from the mother to
the fetus.54 Subseguently, Herrera et al. showed that the
transfer of glucose across the placenta to the fetus is
dependent on the degree of glycemia in the mother. As a
conseguence of the placental glucose transfer, the fetus
becomes hyperglycemic.™ Maternal diabetes in rats also
seems to cause changes in uteroplacental blood flow, the
number of placental glucose transporters, and placental
storage and release of glucose."
The hyperglycemia-hyperinsulinism theory holds that
maternal hyperglycemia causes fetal hyperglycemia which in
turn leads to fetal islet tissue hypertrophy with increased
secretion of insulin indicated by the often found
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hyperinsulinemia at birth.79 The hyperinsulinemia leads to
increased anabolism and growth in the fetus. Freinkel25 has
expanded on this theory by stating that increased glucose,
amino acids, and FFA in the gestational diabetic mother all
contribute to the hyperinsulinemic state of the fetus. By
using chronically catheterized fetal lambs, Phillips et al.
showed that the induction of fetal hyperglycemia leads to an
increased fetal metabolic rate and an increased uptake of
glucose and lactate." These changes occurred at eguivalent
maternal glucose levels of 12 0-150 mg/dl and occurred
without fetal hypoxia. However, severe hyperglycemia
induced fetal hypoxia to a level that is associated with
fetal metabolic acidosis and death." Digiacomo and Hay"
found that there is little influence of insulin on placental
glucose transport so that small changes in fetal insulin
concentration have little effect on glucose utilization by
the fetus. Their study also indicates that there may be a
threshold of glucose concentration that must be surpassed in
order for secretion of fetal insulin to be stimulated."
Thus there is some preliminary data, that shows that the
fetus is indeed influenced by the maternal metabolic
environment in ways explained by the theory of
hyperglycemia-hyperinsulinism, however, the role of insulin
in the fetus is not clear and the occurrence of an early
growth delay with congenital anomalies could suggest that
the fetus is not receiving enough nutrients instead of too
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much. More data is needed on the metabolic interplay
between mother and fetus.
Thus far, investigators have focused on the mechanisms
behind insulin resistance, fasting hyperglycemia, oxidative
versus non-oxidative disposal of nutrients and maternal-
fetal metabolic interactions in order to delineate the
significance of the diabetogenicity of pregnancy. Most
studies in these areas have been done on either obese or
NIDDM subjects or animal models for pregnancy, with little
research on pregnant women. It is obvious at this point
that "insulin resistance" is a general term which has been
applied to many situations in which insulin's effects are
abnormal. A defect anywhere in the pathway from insulin's
secretion, to its arrival at the receptor, to its adeguate
binding to the receptor, to the postreceptor cascades which
activate the enzymes of glucose, fatty acid, and amino acid
oxidative and nonoxidative metabolism may be involved. Thus
far, good technigues have evolved to distinguish insulin
resistance due to a problem with secretion versus receptor
defects versus postreceptor defects; however, the exact
seguence of events is far from determined.
Evolution of Technology
Methods for studying carbohydrate metabolism have evolved
dramatically over the last 30 years. Glucose tolerance
tests were first used to show that beta cell deficiency was
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not the only factor to consider in the etiology of diabetes
but because there is a feedback loop between glucose and
insulin they were unable to distinguish between the effects
of glucose and insulin.*2'5 Insulin tolerance tests evoke
many counterregulatory hormone responses that oppose
insulin84 and thus the actions of insulin alone cannot be
determined. Forearm perfusion studies will avoid these
problems, however, you only receive information on
peripheral tissues with no influence from the liver.'5
Infusion of somatostatin or epinephrine to inhibit
endogenous insulin secretion has the drawback of using
confounding agents which may influence the results.85 The
glucose clamp technigue, an application of the negative
feedback principle regulating serum glucose, was made
possible by the development of a rapid analyzer of blood
glucose concentration.86 Developed by Andres, DeFronzo and
colleagues,878"9 the glucose clamp technigue allows the
investigator to hold the blood glucose at a hyperglycemic
value, with no addition of exogenous insulin, and then
measure beta-cell responses to glucose. Similarly, by
holding the blood glucose at a constant value, with a
programmed insulin infusion and variable glucose infusion,
the sensitivity and responsitivity of tissues to insulin can
be measured. Thus various metabolic situations, such as:
hyperinsulinemia, hyperglycemia, euglycemia, or hypoglycemia
can be studied under normal physiologic conditions. Once
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steady state conditions are achieved and if hepatic glucose
production is completely suppressed, the amount of glucose
infused represents glucose utilization minus any urinary
loss. If hepatic glucose production is not suppressed, then
by using isotopic measurements the rates of endogenous
glucose production and total glucose utilization can be
determined. In addition, by using a spectrum of steady
state insulin concentrations in the same subject, the
investigators can determine the insulin dose-response curves
mentioned above that were used to distinguish insulin
sensitivity from insulin responsiveness.
Indirect calorimetry has been used in this context to
determine the fates of intracellular glucose in various
insulin resistant states and under various hyperglycemic and
hyperinsulinemic conditions only recently.'5" The
theoretical basis of indirect calorimetry is to estimate
metabolic rate by measurements of oxygen consumption and
carbon dioxide production. Direct calorimetry measures
total heat loss from the body and is a much more cumbersome
and invasive procedure, whereas indirect calorimetry
measures energy production by the body with the assumption
that all the oxygen is used to metabolize fuels and all
carbon dioxide that is produced is expired, and is a much
simpler method with current technology.50 By combination
with tracer technigues, indirect calorimetry can be used to
measure the disposition of various substrates.
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Our Study
The studies reported in this thesis were designed to
investigate the insulin resistance of pregnancy using non
pregnant women compared to normal pregnant women and
gestational diabetics. Ryan et al.50 used these three groups
and the euglycemic clamp technigue to try to characterize
the nature of insulin resistance of pregnancy. They
verified that normal human pregnancy is accompanied by
hyperinsulinemia and normal insulin binding to erythrocytes.
They also showed that the insulin resistance of pregnancy
and gestational diabetes includes a decreased sensitivity to
insulin and "suggested" that there was also a component of
decreased responsitivity to insulin. They were not able to
prove this because complete insulin dose-response curves
were not done; only two points on the curve were examined.
This has been the only complete study using the clamp
technigue on pregnant women until now.
Our study utilizes the hyperglycemic clamp technigue
which will allow us to study glucose utilization during
hyperglycemia, the insulin secretory response during a
glucose challenge, and the tissue sensitivity to insulin
during hyperglycemia in nondiabetic and gestational diabetic
pregnancies. In addition, we examine various hormonal





Three groups of women were studied. Group 1 were
nondiabetic, non-pregnant control subjects (NDNP) (n=9) .
Group 2 were nondiabetic, pregnant women with normal glucose
tolerance (NDP) (n=9) . Group 3 were pregnant women with
gestational-onset diabetes during this pregnancy controlled
by diet alone (GDP) (n=4) . The pregnant groups have been
further subdivided by gestational age. NDP-2 (n=2)
represents non-diabetic pregnant women in the second
trimester of pregnancy and NDP-3 (n=7) in the third
trimester of pregnancy. GDP-2 (n=l) represents gestational
diabetic women in the second trimester of pregnancy and GDP-
3 (n=3) in the third trimester of pregnancy. Clinical
descriptions of these women are given in Table 2 . There is
no difference in mean age, weight, or pre-pregnancy body
mass index between the normal pregnant women and the control
group. There is no significant difference in the
gestational age between the normal pregnant group(29 . 6+/-
4.7) and the gestational diabetic group (31 . 8+/-4 . 7) . The
gestational diabetic group (32.5 yrs.) is significantly
older than the NDP group (26.0 yrs.), but there is no
significant difference in pre-gravid weight or BMI between
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the gestational diabetic group and the non-diabetic pregnant
group. Body mass index (BMI) was used along with weight and
surface area to compare the groups. Body mass index was
felt to be a better comparison than using height-weight
tables since the body mass index has a low correlation with
height and a high correlation with body fat."* The criteria
used to diagnose gestational diabetes by the OGTT were those
of Carpenter and Coustan.1 The control group (NDNP) was
matched as closely as possible to the NDP subjects by age
and pregravid body mass index. All NDP subjects had at
least one normal oral glucose tolerance test during
pregnancy and were otherwise healthy, with no complications
during this pregnancy. All NDNP subjects had a normal OGTT,
were not taking oral contraceptives or other drugs that may
influence carbohydrate metabolism, and had no recent change
in body weight or carbohydrate diet. The GDP group were all
diagnosed with gestational diabetes prior to entering the
study by standard three hour glucose tolerance testing and
all women were otherwise healthy with no complications
during this pregnancy. All subjects were instructed to fast
from the night before the study. The study was fully
explained to all subjects, including the nature, purposes,
and risks, and all subjects gave their informed, voluntary
written consent before their participation. The
experimental protocol was approved by the Human
Investigation Committee of Yale University School of Medicine.
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Experimental Protocol
The studies were performed with the subjects supine or
on their side, beginning at 8:00 A.M. after an overnight
fast of 10 hours. A Teflon catheter was inserted into an
antecubital vein for infusion of glucose. Another Teflon
canula was inserted into a wrist vein in a retrograde
fashion for blood sampling, and kept patent by an isotonic
saline drip. The hand was then placed in a box that was
heated to 70 degrees C. In this manner, it was possible to
collect "arterialized" venous blood samples through the
wrist cannula.'5 Urine was collected at the end of the study
to determine volume, urinary nitrogen excretion, creatinine,
and glucose loss.
Hyperglycemic clamp procedure
The hyperglycemic clamp technigue has been thoroughly
described elsewhere."* The goal of our hyperglycemic clamp
study was to raise the plasma glucose concentration rapidly
to a fixed hyperglycemic plateau (125 mg/dl above fasting
values) and to maintain it at that level for 2 hours.
Group Sub j .
No.
Age (yrs) Gestational Age Weight kg BMI kg/m2 •IBW
%
NDNP 1 24 58.06 21.99 102%
NDNP 2 40 64.54 22.33 104%
NDNP 3 20 65.91 22.73 106%
NDNP 4 20 96.36 30.38 141%
NDNP 5 25 58.18 21.80 101%
NDNP 6 38 74.09 26.75 124%
NDNP 7 24 76.00 29.69 138%
NDNP 8 25 63.63 24.24 113%






NDP-3 1 33 34 wks 57.61 22.16 103%
NDP-3 2 26 31 wks 52.16 22.48 105%
NDP-2 3 28 20 wks 59.87 22.68 105%
NDP-3 4 23 31 wks 68.04 25.77 120%
NDP-2 5 29 22 wks 55.34 21.28 99%
NDP-3 6 23 32 wks 72.58 29.26 136%
NDP-3 7 26 33.5 wks 83.0 30.74 121%
NDP-3 8 22 31 wks 73.93 25.15 117%








GDP-3 1 36 33.5 wks 49.90 21.14 98%
GDP-2 2 34 24 wks 90.72 32.28 150%
GDP-3 3 35 33 wks 71.21 26.09 143%
GDP-3 4 25 36.5 wks 78.02 28.57 133%
Mean 32.5 31.8 72.46 27.02 131%
Table 2: Characteristics of subject population. NDNP (Non-diabetic, non-pregnant); NDP (Non-diabetic pregnant);
GDM (Gestational diabetes mellitus pregnant) *IBW calculated from BMI/Desirable BMI (21.5)?1 Pre-pregnancy
weight used for pregnant subject's calculations Mean values shown with standard error and there are no statistical
differences between NDNP group and NDP group. GDP group is significantly older than the NDP group.
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This was done in two steps: first, the plateau was reached
by infusing a priming dose of glucose in a logarithmically
decreasing manner to achieve the desired level of
hyperglycemia quickly. Secondly, the plasma glucose
concentration was measured every 5 minutes, and a 2 0%
glucose infusion was adjusted based on a negative feedback
principle (if the measured glucose concentration was greater
than the plateau value, then the infusion rate was decreased
and visa versa) in order to maintain the plasma glucose
constant at the desired hyperglycemic plateau.™ Plasma
samples for glucose were drawn at 10 minute intervals during
the initial 1/2 hour before glucose infusion had begun and
at 2 minute intervals during the initial 10 minutes of
infusion and every 5 minutes thereafter. Plasma samples for
insulin and C-peptide were drawn at 10 minute intervals
during the initial 1/2 hour before glucose infusion had
begun, then at 2 minute intervals during the initial 10
minutes of glucose infusion, and finally at 10 minute
intervals thereafter. Plasma samples for glucagon were
measured twice during the basal period and 4 times during
hyperglycemia. Growth hormone was measured twice during the




Plasma glucose concentration was determined in duplicate
by the glucose oxidase method using a Beckman Glucose
Analyzer II (Beckman Instruments Inc., Fullerton, CA) .
Insulin, C-peptide", glucagon and growth hormone were
measured by radioimmunoassay.
Calculations
The plasma insulin response during the hyperglycemic
clamp procedure is biphasic so first phase insulin secretory
response was calculated from 0 to 10 minutes (first phase
insulin secretion) and second phase insulin secretory
response from 20 to 120 minutes by taking the sum of the
concentrations divided by the time interval, minute by
minute. The fasting insulin concentration represents the
mean of at least four values. C-peptide calculations were
similar to those performed for insulin. During steady-state
plasma glucose concentration, which occurs during the last
hour of hyperglycemia, hepatic glucose production is
completely suppressed*4 (DeFronzo et al., 1983 showed that,
by using the hyperglycemic clamp in combination with hepatic
vein catheterization and [!H-3] glucose infusion, raising the
plasma glucose concentration to 13 7 +/- 3 and 224 +/- 2
mg/dl could suppress hepatic glucose production by >90% at
the lower concentration and completely at the higher
concentration) . Therefore, the amount of glucose infused
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must equal the amount of glucose taken up (M) by all the
cells of the body after a small correction for urinary
glucose losses.' M is essentially a measure of glucose
tolerance in hyperglycemic clamp studies since the plasma
glucose concentration is fixed so the amount of glucose
infused becomes the measure of tolerance. The rate of
glucose metabolism during the hyperglycemic clamp procedure
(mg/sq.meter of body surface area/min) was calculated at 2 0
minute intervals according to the equation: M = INF
- UC -
SC, where INF is the glucose infusion rate, UC is the
urinary correction for loss of glucose, and SC is space
correction factor.*7 During the last hour of the
hyperglycemic clamp, the M/I ratio provides an estimate of
the quantity of glucose metabolized per unit of insulin (I)
concentration under stable hyperglycemic conditions and is
thus a reasonable index of tissue sensitivity to insulin."
Statistics
All data are expressed as mean +/- standard error of the
mean. Statistical significance was defined as P<0.05. Two
group comparisons of the means were performed by unpaired
and paired Student T-Tests. Correlations between variables
were examined by Spearman's Rank Correlation analysis.
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Note
The studies performed on the NDP and GDP groups were
performed by myself and Dr. Diamond as the principle
investigators. The control subject data (NDNP) is taken
from other studies performed by Dr. Diamond and his co




Fasting blood glucose values were significantly lower in
both pregnant groups (NDP 76.06+/-1.53 mg/dl, GDP 79.75+/2-
1.71 mg/dl) than in non-pregnant controls (87. 58+/-1. 34
mg/dl) p<0.05 (Table 3). There was no significant
difference in fasting glucose blood concentrations between
normal pregnant women and gestational diabetics and no
significant difference as normal pregnancy progresses from
the second to third trimester.
During the hyperglycemic clamp procedure, the blood
glucose concentration was raised to 125 mg/dl above the
fasting levels and then maintained at this constant level
(Figure 4) . Table 3 shows the results of the mean blood
glucose during the last hour of the study for each group.
By comparing the plasma glucose value over the last hour of
the study, one can see that all groups approach ideal values
of 125 mg/dl above fasting levels.
The mean fasting insulin values for normal pregnant women
in the third trimester of pregnancy (20 . 54+/-3 . 11 uU/ml) is
not significantly higher than controls (14 . 95+/-0. 99 uU/ml)
or normal pregnant women in their second trimester (7.75+/-
2.50 uU/ml) (Table 3). There is no significant difference
between fasting insulin values in normal pregnant women
(17.69+/-3.06 uU/ml) and gestational diabetics (18.40+/-3 .42
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uU/ml) . There is also no significant difference in fasting
insulin values between normal pregnant women in their third
trimester of pregnancy (20.54+/-3 . 11 uU/ml) and gestational
diabetic women in their third trimester (15.44+/-2 . 43
uU/ml) .
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Figure 4: Mean blood glucose levels are plotted against time during the study period for NDNP, NDP, and GDP groups. Time 0 represents
the start of glucose infusion. All groups reached their stable plateau values by 20 minutes into the study and the plateau was maintained for the
remainder of the study period.
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Table 3: Mean fasting glucose, insulin, and C-peptide values (mg/dl) calculated from at least 3 values during the half hour period before the infusion of
glucose. Mean glucose values with standard error for each group during the last hour of the study showing that the actual blood glucose levels attained are
essentially identical to the idealized goal values of 125 mg/dl greater than fasting levels. Mean glucose infusion rate over last hour of the study and mean
M/I ratio over the last hour of the study for each group. GDP-2 has only one subject. Starred values are significantly different from the control group.
Mean first phase and second phase secretion of insulin and C-peptide are shown for each group.
Results of insulin levels over the course of the study
period are shown in Figure 5. First phase insulin secretion
occurs in all groups from 0 to 10 minutes. There is no
shift in the time course of first phase secretion between
groups with the maximum occurring at 4 minutes. There is a
trend towards increasing first phase insulin secretory
response in the third trimester of pregnancy in the NDP
group(108 . 81+/-13 .03 uU/ml) as compared to all other groups
(Fig. 7) although the low number of subjects does not allow
us to prove significance. The GDP group's first phase
insulin secretory response (75 . 90+/-23 . 70 uU/ml) was not
different from controls (79 . 23+/-15 . 76 uU/ml) and to NDP
group's response in the second trimester (48 . 20+/-11. 60
uU/ml) . Mean values with standard error for all groups are
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shown in Table 3. The second phase of insulin secretion
showed a steady rise over the remainder of the study period
in all groups as shown in Figure 5. The mean second phase
insulin secretion over the last hour of the study with
standard error is shown in Table 3 and Figure 5. The NDP
group (195.63+/-39. 68 uU/ml) showed a significant increase
in the phase 2 insulin secretory response over controls
(NDNP) (103.02+/-12.43 uU/ml) p<0.05. The NDP-3 group
6 (228.57+/-43.40 uU/ml) proved to have a significantly
greater second phase insulin secretory response than
controls p<0.05, whereas the NDP-2 group (80. 33+/-4.92
uU/ml) was not significantly different than non-pregnant
controls. The normal pregnant group (195 . 63+/-39 . 68 uU/ml)
trends towards a greater second phase insulin secretory
response over the gestational diabetic pregnant group
(127.93+/-21.70 uU/ml) as well, but more subjects are needed
to prove significance. The GDP groups did not show a
significantly greater second phase insulin secretory
response as compared to controls; however, our data does
tend towards a greater response from gestational diabetics
than non-pregnant controls. There was a significant
positive correlation between the first and second phase




mean plasma insulin values
were plotted against time.
The graph demonstrates the
biphasic plasma insulin
response patterns for non
diabetic non-pregnant
controls (NDNP), non
diabetic pregnant women in




in their third trimester of
pregnancy.
Hyperglycemic Clamp Insulin Values
Figure 5
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Figure 6: Incremental
mean plasma C-peptide
values were plotted over
time of the study. Graph
shows the biphasic plasma
C-peptide response pattern
that mirrors that of
insulin's response in Figure
5.
Hyperglycemic Clamp C-peptide Values
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C-peptide fasting levels follow those of insulin, as
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tend to be greater
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Figure 7: Both first and second phases of the insulin secretory response is plotted for each
group in the study. Each bar is shown with +/- SEM.
1299 . 6+/-507 . 6 pmoles/L) as is true for insulin first phase
secretion (Table 3) . In addition, C-peptide second phase
secretion for the NDP-3 group (2391 . 9+/-565 . 4 pmoles/L) is
not significantly different than the other groups which
again deviates from the pattern seen for insulin.
Figure 8 shows the C-peptide/Insulin secretion for each
group over the first and second phases of secretion. This
data indicates that the C-peptide/ insulin ratio for both
first phase and second phase secretion of the NDP group
(10.83+/-1.71 moles C-peptide/unit insulin x 10% 12.96+/-
2.53 moles C-peptide/unit insulin x 10') and the NDP-3 group
(9.81+/-1.61 moles C-peptide/unit insulin x 10', 11.55+/-
2.56 moles C-peptide/unit insulin x 10') was significantly
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lower than non-pregnant controls (19 . 77+/-1. 77 moles C-
peptide/unit insulin x 10', 25.19+/-2.60 moles C-
peptide/unit insulin x 10') p<0.05. The NDP-2 group tends
towards a lower ratio than controls but greater than that
found in the third trimester. First phase C-peptide/ insulin
ratios for gestational diabetics (24 . 41+/-2 . 40 moles C-











peptide/ insulin ratios of NDP and NDP-3 groups p<0.05. The
second phase C-peptide/ insulin ratios for GDP, GDP-2, and
GDP-3 groups were not significantly different than controls
and tended towards being greater than all normal pregnant
groups, although significance was not proven. In addition,
Figure 8 indicates that the amount of C-peptide per unit of
insulin tends to increase with the second phase of secretion
in non-pregnant controls and normal pregnant women;
















NDNP NDP NDP-2 NDP-3 GDP GDP-2 GDP-3
Figure 9: Mean glucose tolerance (M) is shown with SEM for each group. NDP-3, GDP,
GDP-3 groups are significantly lower than NDNP group. (p<0.05)
correcting for urinary glucose losses and a space correction
factor as long as the hepatic glucose production is






















completely suppressed. The glucose infusion data indicates
that during pregnancy, glucose tolerance significantly
decreases over the last hour of the study period (second
phase of insulin secretion) by about 25% during normal
pregnancy (7.81+/-0.73 mg/kg/min) (N.S.) and by almost 50%
in gestational diabetes (5. 54+/-0. 38 mg/kg/min) (p<0.05) as
compared to non-pregnant controls (10. 60+/-1. 19 mg/kg/min).
Figure 10 shows the change in the glucose infusion rate
during the study period in all groups and demonstrates the
effects of pregnancy and gestational diabetes on glucose
tolerance. Figure 9 and Table 3 display the mean glucose
infusion rates over the last hour of the study for all
groups. Figure 9 indicates that the glucose infusion rate
tends to decrease between the second trimester (9 . 97+/-0 . 57
mg/kg/min) and third trimester (7. 20+/-0.79 mg/kg/min) of
normal pregnancy, but was not proven to be significant.
Both pregnant groups in the third trimester of pregnancy
(NDP-3 7.20+/-0.79 mg/kg/min, GDP-3 5.87+/- 0.27 mg/kg/min)
demonstrated significantly lower glucose uptake than non
pregnant controls (10. 60+/-1. 19 mg/kg/min) p<0.05. There is
a trend towards even lower glucose infusion rates during the
third trimester of pregnancy in gestational diabetics
(5.58+/-0.27 mg/kg/min) than in the third trimester of
normal pregnancy (7.20+/-0.79 mg/kg/min), but this did not
statistical significance possibly because of the low number
of subjects in the gestational diabetic group.
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The M/I ratio (glucose metabolized per unit of insulin
concentration) calculation during the last hour of
hyperglycemia is used as a reasonable index of tissue
sensitivity to insulin.77 The M/I ratios for all groups over
the last hour of the study are shown in Table 3 and in




















NDNP NDP NDP-2 NDP-3 GDP GDP-2 GDP-3
Controls (0.11+ /— Figure ll: M/I ratio is a measure of tissue sensitivity to insulin. Graph shows mean M/I ratios
+/- SEM for each group. NDP-3, GDP significantly lower than NDNP group and NDP-3 less
than NDP-2 (p<0.05).
0.02 mg/kg/min per
uU/ml) . There is also a significantly lower tissue
sensitivity to insulin in the GDP group (0.04+/-0.01
mg/kg/min per uU/ml) as compared to controls (0.11+/-0.02
mg/kg/min per uU/ml) p<0.05; however, we could not prove
significance for the GDP-3 group (0.05+/ -0.01 mg/kg/min per
uU/ml) although they too show much lower tissue sensitivity
to insulin than controls. There is no difference in tissue
sensitivity between gestational diabetic women during the
third trimester of pregnancy (0.05+/ -0.01 mg/kg/min per
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uU/ml) and non-diabetic pregnant women in the third
trimester (0.03+/-0.01 mg/kg/min per uU/ml) . There is also
a significant decrease in the M/I ratio as pregnancy
progresses from the second (NDP-2 0.12+/-0.02 mg/kg/min per
uU/ml) to the third trimesters (NDP-3 0.03+/ -0.01 mg/kg/min
per uU/ml) of normal pregnancy p<0.05.
Glucoregulatory Hormonal Studies
Table 4 and








had siQnif icantlV Figure 12: Fasting and hyperglycemic glucagon values are shown for each group +/- SEM.
lower fasting glucagon concentrations than the non-pregnant
control group during fasting (NDP 95. 00+/-12 . 00 pg/ml, GDP
86.25+/-16.37 pg/ml, NDNP 177 . 00+/-18 . 65 pg/ml) p<0.05.
During hyperglycemic conditions, the normal pregnant group
(NDP 52 .89+/-11.04 pg/ml) had significantly lower plasma





pg/ml) (p<0.05), but the gestational diabetic group (GDP
52. 50+/-15.44 pg/ml) was not significantly different than
controls. In addition, there was no significant difference
in fasting or hyperglycemic glucagon values between normal
pregnant women (NDP) and gestational diabetic women (GDP) .
NDNP NDP NDP-2 NDP-3 GDP GDP-2 GDP-3



























































Table 4: Hormonal Values Under Fasting and Hyperglycemic Conditions for All Groups. Significantly different values are denoted by
"
All groups showed a significant decrease in plasma glucagon
values during hyperglycemia in proportion to the initial
fasting plasma glucagon values (p<0.05). The pregnant
groups did not show a more significant fall in glucagon
values from the control group or from each other.
Table 4 and Figure 13 show the results from the growth
hormone studies. Growth hormone results show that both
pregnant groups had significantly higher growth hormone
values than the control group under both fasting (NDP
12.00+/-0.87 ng/ml, GDP 11.98+/-0.72 ng/ml, NDNP 4.70+/-2.45
ng/ml) and hyperglycemic conditions (NDP 11.60+/-0.78 ng/ml,
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Figure 13: Fasting and hyperglycemic growth hormone levels for all groups shown +/- SEM.
of the groups showed a significant change in growth hormone
levels over the two hour period of hyperglycemia.
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DISCUSSION
Many reports indicate that pregnancy is a diabetogenic
state in that the mother's glucose metabolism is
characterized by both exaggerated glucose and insulin
responses to food ingestion and by insulin resistance.
Insulin resistance has come to mean any condition which
requires supranormal amounts of insulin to maintain
normoglycemia. The theoretic causes of insulin resistance
include: abnormal beta-cell secretion, circulating insulin
antagonists, or a tissue insensitivity to insulin's effects
which can be further grouped into receptor defects and
postreceptor defects.
"^
Though there have been studies
examining the insulin resistance during normal pregnancy and
gestational diabetes using the euglycemic clamp, this study
utilizes the hyperglycemic clamp procedure which allows us
to examine: 1. insulin secretory response and 2. tissue
sensitivity to insulin under hyperglycemic conditions.
There is a great amount of evidence that points to the
existence of insulin antagonism in late pregnancy; however,
the paradox of low fasting glucose concentrations in late
pregnancy as compared to non-pregnant women remains. Our
study supports this fact with fasting glucose concentrations
in both the normal and gestational diabetic pregnant groups
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9-13% lower than non-pregnant controls. A review of the
subject by Weiss, 1988, reveals similar values." Since
there is a basic resistance to insulin's actions, the often
elevated fasting insulin values alone cannot account for the
fasting hypoglycemia." The reasons for this are not
entirely clear but some speculations are that the diffusion
of nutrients across the placenta to the fetus may contribute
to the rapid decline of glucose in maternal circulation.
Also, there is a progressive rise in ketone body
concentrations which may suppress the release of
gluconeogenic amino acids such as alanine from skeletal
muscle." Finally, there may be other hormonal influences
leading to divergence of glucose precursors to other areas
leading to decreased endogenous glucose production.
Other researchers have shown an increased insulin
secretion in response to hyperglycemia in normal pregnancy
and gestational diabetes, but the glycemic stimulus varied
in magnitude and duration.100"""'2 Our study extends these
findings and shows that with the same increase in blood
glucose over the same duration of time, normal late
pregnancy was in fact characterized by an increased first
and second phase insulin secretory response by approximately
37% and 55% respectively over non-pregnant controls (Figure
7) . Gestational diabetic pregnant women, on the other hand,
did not show as great an increase in insulin secretion with
hyperglycemia which confirms others' findings.'0"04 Thus,
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their beta-cells appear to be unable to adeguately increase
their insulin secretion. This observation is consistent
with prior speculation that the primary defect in
gestational diabetes mellitus is an inadeguate ability to
increase insulin secretory capacity.
C-peptide secretion does not mirror that of insulin in
that there is no increase in C-peptide secretion in the
normal pregnant group during the third trimester (Figure 6) .
Figure 8 demonstrates the relationship between C-peptide and
insulin secretion. The C-peptide/ insulin ratio seems to
decrease progressively with increasing gestation in normal
pregnancy. The decreasing C-peptide/ insulin ratio with
increasing gestation could be due to any of the following:
1. a progressive increase in insulin secretion over C-
peptide secretion as pregnancy progresses, 2. a decreased
metabolism of insulin as pregnancy progresses, 3. an
increased metabolism of C-peptide (possibly by the
placenta)105 as pregnancy progresses, 4. increased renal
clearance of C-peptide in the normal pregnant group during
the third trimester of pregnancy.- and 5. cross reaction in
the insulin or C-peptide assay with proinsulin or each
other; however, the same assay was used for all groups and
you would expect a uniform increase or decrease among all
groups. The absolute concentration
of proinsulin is
increased in late gestational diabetes and normal pregnancy,




Therefore, there is no
evidence that an increase in insulin or C-peptide secretion
could be accounted for by cross-reactivity with proinsulin.
The interpretation of the data depends on whether insulin
and C-peptide are indeed secreted in eguimolar amounts"40
through pregnancy. If they are, then either insulin
degradation is inhibited or C-peptide degradation enhanced
with increasing gestation. There are many reports that
insulin degradation by the liver is unchanged in
pregnancy.
u,°""
On the other hand, C-peptide is not cleared
by the liver" but by the kidney- There is evidence that C-
peptide crosses and is metabolized by the placenta, whereas
proinsulin and insulin do not."" In this scenario, C-peptide
would have a greater volume of distribution as well as
decreased amounts contributing to lower maternal C-peptide
concentrations. In addition, the metabolism of C-peptide
would be dependent on the size and stage of the placenta,
thus changing with increasing gestation. Therefore, we must
reconsider whether we can reliably compare C-peptide
concentrations between pregnant and non-pregnant women as
well as comparing pregnant women at different stages in
pregnancy.
The picture is further complicated by the gestational
diabetic pregnant data. Gestational diabetic pregnant women
do not decrease their C-peptide/ insulin ratio as normal
pregnant women do and do not appear to have a significantly
64
different ratio than controls. C-peptide secretion for the
gestational diabetic group, as in the control group, appears
to reflect insulin secretion unlike that found in late
normal pregnancy as described above. In any event, it is
clear that whatever the mechanism (as discussed above) that
may be occurring in late normal pregnancy to cause the
disparity between insulin and C-peptide levels, this
mechanism does not appear to be occurring in late
gestational diabetic pregnancies. Comments cannot be made
on the change in C-peptide to insulin ratio with increasing
gestation in the gestational diabetic pregnant groups
because of the inadequate number of subjects.
During the hyperglycemic clamp procedure, we assume
hepatic glucose production is suppressed so that glucose
uptake during the study is a measure of glucose tolerance.
Despite the increase in insulin secretion during late
pregnancy, in Figure 9 we see that both normal and
gestational diabetic pregnant groups exhibit a lower glucose
tolerance than non-pregnant controls. Gestational diabetics
trend towards even lower glucose tolerance than normal
pregnant women. We were unable to prove significance
because of the low number of subjects. In addition, this
glucose intolerance seems to worsen with increasing
gestation in normal pregnancy. No conclusion can be drawn
on the change in glucose tolerance with increasing gestation
in the gestational diabetic groups because of the inadequate
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number of subjects in the second trimester. Thus, normal
pregnancy in general is characterized by a decrease in
glucose uptake all the while insulin secretion is
increasing; therefore, pointing to a state of insulin
resistance. The glucose intolerance is not apparent in our
study until the third trimester of normal pregnancy; the
second trimester of normal pregnancy appears to be
associated with normal glucose tolerance. In fact, insulin
action on carbohydrate metabolism has been shown to be
enhanced during early pregnancy with an improved intravenous
glucose tolerance.441"
The M/I ratio provides an estimate of the quantity of
glucose metabolized (M) per unit of insulin (I)
concentration under hyperglycemic conditions. This is used
as a measure of tissue sensitivity to insulin. (It is
important to understand that when we talk of the M/I ratio
being a measure of tissue sensitivity to insulin, we are not
referring only to receptor defects but to the entire
spectrum of receptor and postreceptor defects. Only
Euglycemic Clamps can distinguish between receptor and
postreceptor defects as shown in Figure 3. Therefore, we
use "tissue sensitivity" as a general term describing how
susceptible the tissue is to insulin's actions for whatever
cellular mechanism.) Our study shows that late pregnancy, in
both normal and gestational diabetic pregnancy, is
characterized by a tissue resistance to insulin. There is
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no apparent difference in tissue sensitivity to insulin
between normal pregnant and gestational diabetic groups in
the third trimester of pregnancy which may indicate that the
cellular mechanisms leading to insulin resistance may not
differ in gestational diabetes from normal pregnant women.
However, again it must be stated that hyperglycemic clamps
do not allow us to distinguish the different cellular
mechanisms involved in creating insulin resistance.
In addition to there being a marked reduction in tissue
sensitivity to insulin during late pregnancy, the tissue
sensitivity to insulin was normal to increased in the second
trimester of normal pregnancy. Again, comment cannot be
made on the change occurring between the second and third
trimester of the gestational diabetic pregnancies. More
data would help us to determine if in fact the M/I ratio is
increased in early pregnancy. This would be consistent with
the findings that estrogens, which rise very early in
pregnancy, have been shown to increase the sensitivity of
both adipose and skeletal muscle tissue to insulin109"0 and
others have found an increase in glucose disappearance rates
after an IVGTT in early pregnancy."1 However, other
researchers have not found that estrogens increase tissue
sensitivity to insulin.4""
In any case, late pregnancy does seem to be
characterized by insulin resistance at the tissue level.
The purpose of this insensitivity appears to be to allow the
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fetus greater concentrations of blood glucose and thus
greater flux of glucose across the placenta. This is
necessary in late pregnancy when the majority of fetal
growth occurs (Figure 1) . Our data seems to indicate that
this resistance does not develop to counteract the great
increases in insulin secretion but visa versa. Since early
pregnancy is not characterized by an increase in insulin
secretion, it would not make sense for the body to increase
insulin secretion primarily in late pregnancy since this
would only serve to decrease plasma glucose concentration.
It does make sense to decrease tissue sensitivity to insulin
as pregnancy progresses which would lead to decreased
glucose uptake by the maternal tissues allowing greater
plasma glucose concentrations and greater transport of
glucose to the fetal compartment. However, the beta-cells
respond to glucose concentrations as a primary stimulus thus
there is an obligatory increase in beta-cell insulin
secretion secondarily in response to elevated blood glucose
concentrations. This theory is entirely consistent with
this study's data as well as others.441""4
The primary stimuli and mechanisms that may lead to the
initial decrease in tissue sensitivity to insulin in
pregnancy have not been elucidated. It
makes sense that
many of the changes in insulin sensitivity and insulin
secretion during normal pregnancy and gestational diabetes
be attributed to the many hormonal changes that occur during
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pregnancy. Our study investigated some of these hormones.
Other studies have found little evidence that glucagon
secretion or action is altered during pregnancy"424470 and our
study supports this. On the other hand, growth hormone
excess can cause carbohydrate intolerance by increasing
postprandial hepatic release of glucose partly by impairing
suppression of gluconeogenesis and by decreasing
postprandial glucose uptake.54 Although our study showed a
significant increase in growth hormone with pregnancy, it
was not significantly changed with hyperglycemia and levels
never came close to those used experimentally. In addition,
there was no difference in growth hormone levels between
normal pregnant women and gestational diabetic women.
Therefore, we conclude that there could be an effect of
growth hormone on the insulin resistance of pregnancy, but
it does not appear to be the force driving the differences
in glucose metabolism between normal pregnant and
gestational diabetic women. Thus far, no gestational
hormone has been shown to directly lead to the tissue
resistance to insulin found in pregnancy.
Though there is no definitive answer on the initial
hormonal stimulus leading to insulin resistance in
pregnancy, many of the
cellular mechanisms of resistance
have been explored by others. The available data on insulin
receptor binding in normal pregnant women is conflicting
with increased insulin binding to monocytes,115 unchanged
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binding to monocytes,"6 and decreased binding to monocytes'"
and adipocytes'" has been reported. Andersen et al., 1986
found an increased insulin binding to monocytes in normal
midpregnancy followed by a significant decrease in late
normal pregnancy. The ID50 remained unchanged. They also
found a decreased insulin binding to adipocytes in late
normal pregnancy at delivery as compared to non-pregnant
controls.96 These findings point to the possibility that
changes in insulin receptors lead, in part, to the insulin
resistance of pregnancy.
There have been other related states to pregnancy such
as obesity and NIDDM that have been shown to have a primary
defect in tissue sensitivity to insulin. The mechanism has
been examined using the euglycemic clamp technique to create
dose-response relationships between serum insulin
concentration and glucose disposal rates (M)
(Figure 3) .6'64 Kolterman et al., 1980, 1981, showed that the
mechanisms of insulin resistance in NIDDM and obesity result
from heterogeneous causes. Both states are characterized by
a decreased number of insulin receptors on the cell surface.
However, the more severe diabetics and more insulin
resistant obese subjects also exhibited a post-receptor
defect. In addition, this post-receptor defect was not
found to occur in liver tissue. A post-receptor defect in
itself can be a heterogeneous group of defects involving any
point in the intracellular cascade that converts the
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stimulus of insulin binding to its receptor to actual
glucose uptake by the cell. Andersen, 1990 concluded after
reviewing studies on insulin target tissues in pregnancy,
that skeletal muscle is probably an important site for the
insulin resistance observed in late human pregnancy. He
also concluded that adipose tissue does not seem to be
involved in the pregnancy induced increased peripheral
resistance at term."4
To characterize this resistance further, Ryan et al.,
1985 performed a limited euglycemic clamp procedure on
normal pregnant women late in pregnancy and gestational
diabetic women. They used a two-dose euglycemic clamp which
did not allow them to distinguish between an impairment in
insulin responsivity (post-receptor defect) and a combined
defect where there is a decreased number of insulin
receptors and a defect in insulin responsivity. They found
that the insulin resistance of pregnancy is associated with
a decrease in insulin responsivity which indicates there is
a post-receptor defect leading to insulin resistance;
however they could not rule-out a combined defect. In
addition, they found that this defect disappeared post
partum and that gestational diabetics appeared to have a
greater decrease in insulin resistance and greater reduction
in "maximum" of the insulin dose-response curve as compared
to normal pregnant women indicative of a more severe defect
in insulin responsivity of gestational diabetic women.50
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Insulin binding studies in gestational diabetics seem to
indicate that insulin binding was similar to normal
pregnancy but the ID50 was significantly lower in gestational
diabetics in late pregnancy as compared to normal pregnant
women.96 This seems to indicate that there is a decrease in
insulin receptor number on monocytes of gestational
diabetics as compared to normal pregnancy.70*
Our study's data on gestational diabetes is also
consistent with the hypothesis that the primary defect in
glucose tolerance of pregnancy is a tissue insensitivity to
insulin. Our data indicates that gestational diabetic women
show a decreased tissue sensitivity to insulin in late
pregnancy that is not significantly different from the
sensitivity in normal pregnant women. However, gestational
diabetics did not exhibit an increased insulin secretory
response in an attempt to counteract the insulin resistance
in late pregnancy as normal pregnant women had, presumably
because their beta-cells are unable to increase their
insulin release and/or production.5'"5 This in turn, leads
one to assume that gestational diabetics would show even
worse glucose tolerance in late pregnancy than normal
pregnant women and in fact,
our data is consistent with this
idea. Andersen"4 points out that pregnant women with a
greater pregnancy- induced
tissue insensitivity to insulin
than normal pregnant women, but who can simultaneously
sufficiently increase their insulin secretory response, will
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not be discovered by the usual OGTT screening procedure.
Thus, it seems that gestational diabetic women are
discovered because of their inability to sufficiently
increase their insulin secretion. Fischer et al., 1980"5,
makes the statement that "in the non-pregnant state
intravenous glucose tolerance may be primarily related to
insulin sensitivity while during pregnancy it may be related
to the degree of compensatory hyperinsulinism.
" The
experience in this study supports this hypothesis.
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